Ariad Pharmaceuticals Inc fka ARIA

[LUMA14]

Ponatinib for chronic myeloid leukaemia: future perspectives

link to abstact

Ponatinib is a third-generation, multi-kinase inhibitor that has been shown to be more potent in vitro than any other tyrosine kinase inhibitor against BCR-ABL wild-type and mutated clones. Ponatinib was shown to be extremely effective in treatment-resistant or intolerant patients in phase 1 and phase 2 studies, irrespective of mutational status determined at baseline.1,2 Therefore, ponatinib was approved for use in patients with refractory Philadelphia chromosome-positive chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia, including patients with the BCR-ABL T315I mutation.